<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03802487</url>
  </required_header>
  <id_info>
    <org_study_id>PKM15402</org_study_id>
    <secondary_id>2017-004937-94</secondary_id>
    <secondary_id>U1111-1200-2077</secondary_id>
    <nct_id>NCT03802487</nct_id>
  </id_info>
  <brief_title>Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects</brief_title>
  <official_title>A Phase 1, Single-Center, Open-Label, Two-Period, One-Sequence, Single Dose Study to Determine the Absolute Bioavailability of Sotagliflozin in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the absolute bioavailability of sotagliflozin via administration of an intravenous&#xD;
      (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled&#xD;
      sotagliflozin without charcoal administration&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the PK of sotagliflozin and its main metabolite sotagliflozin-3-O-glucuronide&#xD;
           (M19) after a single oral dose of sotagliflozin and an IV microdose of a&#xD;
           14C-sotagliflozin tracer without charcoal administration&#xD;
&#xD;
        -  To assess the safety and tolerability of single doses of sotagliflozin when administered&#xD;
           with and without charcoal&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is up to 54 days including a screening period of up to 28&#xD;
      days, period 1 of 8 days, period 2 of 8 days, a washout period of at least 10 days, and a&#xD;
      follow up period of 12-16 days.&#xD;
&#xD;
      The oral drug Sotagliflozin is metabolized by the liver and released in the bile juice into&#xD;
      the intestine. Ingestion of charcoal a few hours after the drug administration circumvents&#xD;
      the re-uptake of the drug from the intestine back into the blood circulation; instead,&#xD;
      Sotagliflozin is eliminated with the feces. By comparison of Sotagliflozin drug&#xD;
      administration with and without charcoal, the extent of this so-called enterohepatic&#xD;
      circulation can be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Actual">March 28, 2019</completion_date>
  <primary_completion_date type="Actual">March 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter: Absolute Bioavailability (F)</measure>
    <time_frame>Baseline to Day 8 of period 1 (without charcoal)</time_frame>
    <description>Absolute Bioavailability (F) will be a composite endpoint and include Area under plasma concentration (AUC) dose normalized for intravenous (IV) 14C-IMP AUClast dose normalized for oral Investigational Medicinal Product (IMP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Area under the curve (AUC) for oral investigational medicinal product (IMP)</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve extrapolated to infinity for oral IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC for IMP metabolite</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve extrapolated to infinity for IMP metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC for IV 14C-IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve extrapolated to infinity for IV 14C-IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUC for 14C-IMP metabolite</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve extrapolated to infinity for 14C-IMP metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Area under curve versus time (AUClast) for oral IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for oral IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUClast for IMP metabolite</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for IMP metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUClast for IV 14C-IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for IV 14C-IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: AUClast for 14C-IMP metabolite</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax for oral IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Maximum plasma concentration observed for oral IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax for IMP metabolite</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Maximum plasma concentration observed for IMP metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax for IV 14C-IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Maximum plasma concentration observed for IV 14C-IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Cmax for 14C-IMP metabolite</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Maximum plasma concentration observed for 14C-IMP metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: tmax for oral IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Time to reach Cmax for oral IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: tmax for IMP metabolite</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Time to reach Cmax for IMP metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: tmax for IV 14C-IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Time to reach Cmax for IV 14C-IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: tmax for 14C-IMP metabolite</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Time to reach Cmax for 14C-IMP metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: t1/2z for oral IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Terminal half-life (t1/2z) associated with the terminal slope for oral IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: t1/2z for IV 14C-IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Terminal half-life (t1/2z) associated with the terminal slope for IV 14C-IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Clearance (CL/F) for oral IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Apparent total body clearance for oral IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Clearance (CL/F) for IV 14C-IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Apparent total body clearance for IV 14C-IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Vz/F for oral IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Apparent volume of distribution for oral IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Vz/F for IV 14C-IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Apparent volume of distribution for IV 14C-IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Vdss/F for oral IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Apparent volume of distribution at the steady state for oral IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: Vdss/F for IV 14C-IMP</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Apparent volume of distribution at the steady state for IV 14C-IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events</measure>
    <time_frame>Baseline to Day 8 of each period</time_frame>
    <description>Number of subjects with adverse events including serious, non-serious, and treatment emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Sotagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer plus charcoal. The other treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer without charcoal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotagliflozin (SAR439954)</intervention_name>
    <description>Pharmaceutical form: Tablet&#xD;
Route of administration: Oral</description>
    <arm_group_label>Sotagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-microtracer</intervention_name>
    <description>Pharmaceutical form: Solution for injection&#xD;
Route of administration: Intravenous</description>
    <arm_group_label>Sotagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Charcoal</intervention_name>
    <description>Pharmaceutical form: Granules for suspension&#xD;
Route of administration: Oral</description>
    <arm_group_label>Sotagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Male or female subjects, between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          -  Body weight between 50.0 and 120.0 kg, inclusive, if male, and between 40.0 and 100.0&#xD;
             kg, inclusive, if female, body mass index (BMI) between 18.0 and 30.0 kg/m2,&#xD;
             inclusive. BMI between 30.0 and 32.0 is acceptable if investigator judges the subject&#xD;
             to have a high muscle mass.&#xD;
&#xD;
          -  Certified as healthy by a comprehensive clinical assessment (detailed medical history&#xD;
             and complete physical examination).&#xD;
&#xD;
          -  Normal vital signs, ECG and laboratory parameters.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any history or presence of clinically relevant abnormalities at screening which could&#xD;
             interfere with the objectives of the study or the safety of the subject's&#xD;
             participation.&#xD;
&#xD;
          -  Blood donation (400 mL) within 3 months before inclusion.&#xD;
&#xD;
          -  History or presence of drug or alcohol abuse.&#xD;
&#xD;
          -  Smoking regularly more than 5 cigarettes or equivalent per week, unable to stop&#xD;
             smoking during the study.&#xD;
&#xD;
        Excessive consumption of beverages containing xanthine bases.&#xD;
&#xD;
          -  If female, pregnancy (defined as positive β-Human Chorionic Gonadotropin blood test),&#xD;
             breast-feeding.&#xD;
&#xD;
          -  Any medication (including St John's Wort) within 14 days before inclusion with the&#xD;
             exception of menopausal hormone replacement therapy; any vaccination within last 28&#xD;
             days; any biologics given within last 4 months.&#xD;
&#xD;
          -  Any subject in the exclusion period of a previous study.&#xD;
&#xD;
          -  Any subject who cannot be contacted in case of emergency.&#xD;
&#xD;
          -  Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen,&#xD;
             anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and&#xD;
             2 antibodies.&#xD;
&#xD;
          -  Positive result on urine drug screen.&#xD;
&#xD;
          -  Positive alcohol test.&#xD;
&#xD;
          -  Participation in a study in which radioisotopes were administered or in which subject&#xD;
             was exposed to any radiation other than normal background radiation within the 12&#xD;
             months before the screening visit.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site number 8260001</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>April 21, 2022</last_update_submitted>
  <last_update_submitted_qc>April 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03802487
org study id: PKM15402
secondary id: 2017-004937-94
secondary id: U1111-1200-2077
nct id: NCT03802487
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
is us export: No
Primary Objective:

      To assess the absolute bioavailability of sotagliflozin via administration of an intravenous
      (IV) microdose of a 14C-sotagliflozin tracer on top of a single oral dose of unlabeled
      sotagliflozin without charcoal administration

      Secondary Objectives:

        -  To assess the PK of sotagliflozin and its main metabolite sotagliflozin-3-O-glucuronide
           (M19) after a single oral dose of sotagliflozin and an IV microdose of a
           14C-sotagliflozin tracer without charcoal administration

        -  To assess the safety and tolerability of single doses of sotagliflozin when administered
           with and without charcoal
Study duration per participant is up to 54 days including a screening period of up to 28
      days, period 1 of 8 days, period 2 of 8 days, a washout period of at least 10 days, and a
      follow up period of 12-16 days.

      The oral drug Sotagliflozin is metabolized by the liver and released in the bile juice into
      the intestine. Ingestion of charcoal a few hours after the drug administration circumvents
      the re-uptake of the drug from the intestine back into the blood circulation; instead,
      Sotagliflozin is eliminated with the feces. By comparison of Sotagliflozin drug
      administration with and without charcoal, the extent of this so-called enterohepatic
      circulation can be assessed.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Pharmacokinetic (PK) parameter: Absolute Bioavailability (F)
time frame: Baseline to Day 8 of period 1 (without charcoal)
description: Absolute Bioavailability (F) will be a composite endpoint and include Area under plasma concentration (AUC) dose normalized for intravenous (IV) 14C-IMP AUClast dose normalized for oral Investigational Medicinal Product (IMP)
measure: Assessment of PK parameter: Area under the curve (AUC) for oral investigational medicinal product (IMP)
time frame: Baseline to Day 8 of each period
description: Area under the plasma concentration versus time curve extrapolated to infinity for oral IMP
measure: Assessment of PK parameter: AUC for IMP metabolite
time frame: Baseline to Day 8 of each period
description: Area under the plasma concentration versus time curve extrapolated to infinity for IMP metabolite
measure: Assessment of PK parameter: AUC for IV 14C-IMP
time frame: Baseline to Day 8 of each period
description: Area under the plasma concentration versus time curve extrapolated to infinity for IV 14C-IMP
measure: Assessment of PK parameter: AUC for 14C-IMP metabolite
time frame: Baseline to Day 8 of each period
description: Area under the plasma concentration versus time curve extrapolated to infinity for 14C-IMP metabolite
measure: Assessment of PK parameter: Area under curve versus time (AUClast) for oral IMP
time frame: Baseline to Day 8 of each period
description: Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for oral IMP
measure: Assessment of PK parameter: AUClast for IMP metabolite
time frame: Baseline to Day 8 of each period
description: Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for IMP metabolite
measure: Assessment of PK parameter: AUClast for IV 14C-IMP
time frame: Baseline to Day 8 of each period
description: Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast for IV 14C-IMP
measure: Assessment of PK parameter: AUClast for 14C-IMP metabolite
time frame: Baseline to Day 8 of each period
description: Area under the plasma concentration versus time curve
measure: Assessment of PK parameter: Cmax for oral IMP
time frame: Baseline to Day 8 of each period
description: Maximum plasma concentration observed for oral IMP
measure: Assessment of PK parameter: Cmax for IMP metabolite
time frame: Baseline to Day 8 of each period
description: Maximum plasma concentration observed for IMP metabolite
measure: Assessment of PK parameter: Cmax for IV 14C-IMP
time frame: Baseline to Day 8 of each period
description: Maximum plasma concentration observed for IV 14C-IMP
measure: Assessment of PK parameter: Cmax for 14C-IMP metabolite
time frame: Baseline to Day 8 of each period
description: Maximum plasma concentration observed for 14C-IMP metabolite
measure: Assessment of PK parameter: tmax for oral IMP
time frame: Baseline to Day 8 of each period
description: Time to reach Cmax for oral IMP
measure: Assessment of PK parameter: tmax for IMP metabolite
time frame: Baseline to Day 8 of each period
description: Time to reach Cmax for IMP metabolite
measure: Assessment of PK parameter: tmax for IV 14C-IMP
time frame: Baseline to Day 8 of each period
description: Time to reach Cmax for IV 14C-IMP
measure: Assessment of PK parameter: tmax for 14C-IMP metabolite
time frame: Baseline to Day 8 of each period
description: Time to reach Cmax for 14C-IMP metabolite
measure: Assessment of PK parameter: t1/2z for oral IMP
time frame: Baseline to Day 8 of each period
description: Terminal half-life (t1/2z) associated with the terminal slope for oral IMP
measure: Assessment of PK parameter: t1/2z for IV 14C-IMP
time frame: Baseline to Day 8 of each period
description: Terminal half-life (t1/2z) associated with the terminal slope for IV 14C-IMP
measure: Assessment of PK parameter: Clearance (CL/F) for oral IMP
time frame: Baseline to Day 8 of each period
description: Apparent total body clearance for oral IMP
measure: Assessment of PK parameter: Clearance (CL/F) for IV 14C-IMP
time frame: Baseline to Day 8 of each period
description: Apparent total body clearance for IV 14C-IMP
measure: Assessment of PK parameter: Vz/F for oral IMP
time frame: Baseline to Day 8 of each period
description: Apparent volume of distribution for oral IMP
measure: Assessment of PK parameter: Vz/F for IV 14C-IMP
time frame: Baseline to Day 8 of each period
description: Apparent volume of distribution for IV 14C-IMP
measure: Assessment of PK parameter: Vdss/F for oral IMP
time frame: Baseline to Day 8 of each period
description: Apparent volume of distribution at the steady state for oral IMP
measure: Assessment of PK parameter: Vdss/F for IV 14C-IMP
time frame: Baseline to Day 8 of each period
description: Apparent volume of distribution at the steady state for IV 14C-IMP
measure: Safety: Adverse events
time frame: Baseline to Day 8 of each period
description: Number of subjects with adverse events including serious, non-serious, and treatment emergent adverse events
arm group label: Sotagliflozin
arm group type: Experimental
description: One treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer plus charcoal. The other treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer without charcoal.
intervention type: Drug
intervention name: Sotagliflozin (SAR439954)
description: Pharmaceutical form: Tablet
Route of administration: Oral
arm group label: Sotagliflozin
intervention type: Drug
intervention name: 14C-microtracer
description: Pharmaceutical form: Solution for injection
Route of administration: Intravenous
arm group label: Sotagliflozin
intervention type: Drug
intervention name: Charcoal
description: Pharmaceutical form: Granules for suspension
Route of administration: Oral
arm group label: Sotagliflozin
criteria: 
gender: All
minimum age: 18 Years
maximum age: 55 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Clinical Sciences & Operations
role: Study Director
affiliation: Sanofi
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Diabetes Mellitus, Type 2
mesh term: (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
mesh term: Charcoal
sharing ipd: Yes
ipd description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org